Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Primary Malignant Peripheral Nerve Sheath Tumors 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myelomonocytic, Chronic 1Gliosarcoma 1Glioma 1Glioblastoma 1GATA2 Deficiency 1Brain Neoplasms 1Astrocytoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Magnetic Resonance Spectroscopy 14Temozolomide 13Specimen Handling 10X-Rays 7Biopsy 7Nuclear Medicine Department, Hospital 6Radiation 5Phantoms, Imaging 5erdafitinib 4ulixertinib 3trametinib 3larotrectinib 3dabrafenib 3Radiotherapy 3tipifarnib 2selpercatinib 2palbociclib 2olaparib 2ivosidenib 2ensartinib 2binimetinib 2Surgical Procedures, Operative 2Nivolumab 2D2C7-(scdsFv)-PE38KDEL 2veliparib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1temsirolimus 1tazemetostat 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Vorinostat × 30 days × Clear all
NCT00268385 2026-05-07

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

National Cancer Institute (NCI)

Phase 1 Active not recruiting
83 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡